--- title: "Neuronetics | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 41.57 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/295534114.md" datetime: "2026-08-11T12:07:56.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295534114.md) - [en](https://longbridge.com/en/news/295534114.md) - [zh-HK](https://longbridge.com/zh-HK/news/295534114.md) --- # Neuronetics | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 41.57 M Revenue: As of FY2026 Q2, the actual value is USD 41.57 M, beating the estimate of USD 40.17 M. EPS: As of FY2026 Q2, the actual value is USD -0.05, beating the estimate of USD -0.1225. EBIT: As of FY2026 Q2, the actual value is USD 462 K. #### Second Quarter 2026 Financial Highlights - Adjusted EBITDA for Neuronetics, Inc. was $254 thousand in the second quarter of 2026, a significant improvement from a loss of - $5,624 thousand in the second quarter of 2025. - The net loss for the second quarter of 2026 was - $3,439 thousand, an improvement from a loss of - $10,120 thousand in the second quarter of 2025. - Net cash used in operations and investing was - $1.4 million, representing a reduction of $2.3 million compared to - $3.8 million in the second quarter of 2025. #### Segment Revenue (Three Months Ended June 30, 2026 vs. 2025) - NeuroStar revenue was $14.677 million in the second quarter of 2026, a decrease of -2.7% from $15.084 million in the second quarter of 2025. - Greenbrook revenue increased by 16.8% to $26.891 million in the second quarter of 2026, up from $23.024 million in the second quarter of 2025. - Total revenues were $41,568 thousand in Q2 2026, compared to $38,108 thousand in Q2 2025, representing a 9% year-over-year increase. #### Operational Metrics (Three Months Ended June 30, 2026 vs. 2025) - Gross margin increased to 51.1% in the second quarter of 2026, up from 46.6% in the second quarter of 2025. - Gross profit was $21,223 thousand in Q2 2026, up from $17,758 thousand in Q2 2025. - Operating expenses decreased by 12% to $22,724 thousand in the second quarter of 2026, compared to $25,816 thousand in the second quarter of 2025. - Loss from operations improved to - $1,501 thousand in the second quarter of 2026, a significant improvement from - $8,058 thousand in the second quarter of 2025. - The net loss attributable to Neuronetics, Inc. stockholders was - $3.439 million in the second quarter of 2026, an improvement from - $10.120 million in the same period of 2025. #### Cash and Cash Equivalents (As of June 30, 2026 vs. December 31, 2025) - Total cash was $24,947 thousand as of June 30, 2026, down from $34.1 million as of December 31, 2025. - Cash and cash equivalents were $19,197 thousand as of June 30, 2026, compared to $28.134 million as of December 31, 2025. - Restricted cash was $5,750 thousand as of June 30, 2026, compared to $6.000 million as of December 31, 2025. #### Cash Flow Activities (Six Months Ended June 30, 2026 vs. 2025) - Net cash used in operating activities was - $10.429 million for the six months ended June 30, 2026, an improvement from - $20.497 million in the same period of 2025. - Net cash used in investing activities was - $589 thousand for the six months ended June 30, 2026, compared to - $471 thousand in the same period of 2025. - Net cash provided by financing activities was $1.831 million for the six months ended June 30, 2026, a decrease from $18.978 million in the same period of 2025. - The net decrease in cash, cash equivalents, and restricted cash was - $9.187 million for the six months ended June 30, 2026, compared to - $1.990 million in the same period of 2025. #### Annual Performance (2025) - Annual Revenue was $149 million. - Unique Patients Treated were 253,412. - Treatments Administered totaled 9,133,855. - Growth in Patients Treated with TMS increased by 23%. - Growth in Spravato Revenue increased by 57%. #### Financial Position (As of June 30, 2026) - Total Current Assets were $53,230 thousand. - Total Assets were $131,529 thousand. - Total Current Liabilities were $28,309 thousand. - Long-Term Debt, net, was $61,519 thousand. - Total Liabilities were $109,889 thousand. - Accumulated Deficit was - $473,151 thousand. - Total Stockholders’ Equity was $17,850 thousand. #### Operational Metrics - Over 800 sites nationwide utilize NeuroStar TMS. - There are 92 Greenbrook Mental Wellness Centers nationwide. - NeuroStar TMS shows 83% of patients experience measurable relief and 62% achieve full remission. - Spravato demonstrates a 52% remission rate at 4 weeks. #### Business Outlook (Full Year 2026) Neuronetics, Inc. anticipates full-year 2026 total revenue to be between $160 million and $164 million, reflecting a year-over-year growth of 7% to 10%. Gross margin is projected to be between 48% and 50%, with operating expenses estimated at $91 million to $96 million, excluding approximately $4 million in non-cash stock-based compensation. The company expects cash flow from operations and investing to be in the range of - $10.5 million to - $14.5 million. ### Related Stocks - [STIM.US](https://longbridge.com/en/quote/STIM.US.md) ## Related News & Research - [Neuronetics names Nir Naor principal financial and accounting officer](https://longbridge.com/en/news/296141434.md) - [Major Investor Quietly Boosts Stake in Neuronetics With Fresh Buy](https://longbridge.com/en/news/296173637.md) - [Algorhythm Holdings Reports Second Quarter 2026 Financial Results](https://longbridge.com/en/news/296124832.md) - [Flexsteel Q4 2026 Earnings Preview](https://longbridge.com/en/news/296031749.md) - [Neuronetics (NASDAQ:STIM) Major Shareholder Buys $44,240.00 in Stock](https://longbridge.com/en/news/296124556.md)